Business
Beam Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines
About this update from Beam Therapeutics Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines though base-editing, announced today the commencement of a proposed public offering of 4,500,000 shares of its common stock. All of the shares will be offered by Beam. Beam also expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock.\n J.P. Morgan, Jefferies and Barclays are acting as joint book-running managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering. A registration statement on Form S-1 relating to the securities being sold in this offering has been filed with the Securities and Exchange Commission (the “SEC”) but has not yet been declared effective. Before you invest, you should read the prospectus in the registration statement for more complete information about Beam and this offering. An electronic copy of the preliminary prospectus relating to the offering will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus relating to the offering may also be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204, or by emailing [email protected]; Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at 877-821-7388 or by email at [email protected]; or Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-888-603-5847, or email: [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction. About Beam Therapeutics Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base-editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at target...